USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Capability Expansion in Nucleic Acid-based Vaccines is Accelerating the Disruption in Vaccines Globally
18-Apr-2022
North America
Market Research
PCCF-01-00-00-00
HC03531-NA-MT_26454
Frost & Sullivan provides an outlook for the global vaccine industry for 2022 and beyond, including emerging trends and growth opportunities. Innovation, which remains mainstream in vaccine development, is augmenting investments by emerging vaccine developers in designing novel technology platforms, especially for nucleic acid-based vaccines. Spurred by the ongoing pandemic, vaccine developers have accelerated the pace of transformation, and the concepts of manufacturing decentralization, digitization of supply-chain, and increased outsourcing have taken center stage. Moreover, companies entering into public-private-partnerships to capitalize on the current situation are likely to establish synergistic relationships at all levels.
The new vision in 2022 is focused on government authorities having several shifts in vaccine development programs and reaching “zero-dose” children to attain vaccination equity in emerging economies. The tailored and targeted approach used by logistics companies for individual vaccines is providing catalytic support to vendors in the vaccine industry. The adoption of innovative technologies and supply-chain resilience by manufacturers to improve their strategic position in the global vaccine market, while ensuring the accessibility of vaccines remains outcome-based in countries with unmet needs, is a prominently emerging business model. The rising focus on prophylactic management of COVID-19 in 2021-2022 is anticipated to shift toward novel delivery modes of traditional vaccines and on highly prevalent disease areas, such as RSV, HIV, and cancer. Technology transfer is crucial for outsourcing to CDMOs, and the shift toward the development of patient-centric models for vaccine delivery is paramount.
Research Highlights
- Traditional and COVID-19 vaccine market size, including key segments from 2022 to 2027
- Dynamics around COVID-19 vaccination and the path to endemicity
- Role of advancements, such as decentralization, technologies, and new modalities, in driving the vaccine value-chain transformation
- The current and future R&D and investment outlook, and its evolution
- Strategic time-defined growth opportunities for ecosystem participants to focus on in the near future
Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8™
Top Three Strategic Imperatives in the Global Vaccines Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Vaccine Landscape—Key Takeaways
Growth Opportunity Matrix
Scope of Analysis
Vaccines—Introduction and Segmentation
Definitions—By Production System
Definitions—By Technology Type
Definitions—By Technology Type (continued)
Growth Drivers for Vaccines Market
Growth Restraints for Vaccines Market
Vaccine Coverage Rate
Areas of Unmet Vaccine Needs
Government Initiatives in Vaccines Industry, 2021
Vaccine Developers Landscape
Pipeline Snapshot, COVID-19 Vaccines
Pipeline Snapshot, Vaccines, 2021
Vaccines Supply Chain—Key Stakeholders
Vaccines Value Chain—The Expanding Role of Different Stakeholders
Vaccines Distribution Framework
Vaccines Distribution Scenario
Evolving Vaccine Delivery Model—Private Sector Fortifying Distribution
Increasing Role of Digital Technology in Vaccines Supply Chain
Key Partnerships and Collaborations, Traditional Vaccines, 2020–2022
Key Partnerships and Collaborations, COVID-19 Vaccines, 2020–2022
Key Partnerships and Collaborations, COVID-19 Vaccines, 2020–2022 (continued)
Key Manufacturing Partnerships With Bio-CDMOs for Approved COVID-19 Vaccines—US
Key Manufacturing Partnerships With Bio-CDMOs for Approved COVID-19 Vaccines—Europe
Key Strategies in the Vaccine Industry
Technological Advancements in Vaccines Industry
Key Growth Metrics for Traditional Vaccines
Research Methodology
Forecast Assumptions
Revenue Forecast
Revenue Forecast Analysis
Revenue Forecast by Technology Type
Percent Revenue Forecast by Technology Type
Revenue by Production System
Percent Revenue by Region
Competitive Environment
Market Share Analysis
Key Growth Metrics
Research Methodology
Forecast Assumptions
Revenue Forecast
Revenue Forecast Analysis
Revenue by Technology Type
Revenue by Production System
Percent Revenue by Region
Competitive Environment
Market Share Analysis
Companies to Watch From 2022–2027
Companies to Watch From 2022–2027 (continued)
Growth Opportunity 1—Building Capabilities for the Development of Nucleic Acid-based Vaccines for Cancer and HIV
Growth Opportunity 1—Building Capabilities for the Development of Nucleic Acid-based Vaccines for Cancer and HIV (continued)
Promising Key Nucleic Acid-based Vaccines in the Pipeline
Growth Opportunity 2—Pediatric Combination Vaccines for Highly Prevalent Infectious Diseases
Growth Opportunity 2—Pediatric Combination Vaccines for Highly Prevalent Infectious Diseases (continued)
Mitigation Measures for Combination Vaccines
Growth Opportunity 3—Tech Transfer in Emerging Economies to Boost the Production Efficiency and Pace
Growth Opportunity 3—Tech Transfer in Emerging Economies to Boost the Production Efficiency and Pace (continued)
Growth Opportunity 4—Developing Countries Entering Into Licensing and Joint Ventures to Build Domestic Capabilities
Growth Opportunity 4—Developing Countries Entering into Licensing and Joint Ventures to Build Domestic Capabilities (continued)
Growth Opportunity 5—Exploring New Disease Areas to Meet the Growing Need for Immunization
Growth Opportunity 5—Exploring New Disease Areas to Meet the Growing Need for Immunization (continued)
Growth Opportunity 5—Exploring New Disease Areas to Meet the Growing Need for Immunization (continued)
Your Next Steps
Why Frost, Why Now?
List of Exhibits
List of Exhibits (continued)
List of Exhibits (continued)
Legal Disclaimer
List of Figures
- Vaccines: Growth Opportunity Matrix, Global, 2022–2027
- Vaccines: Growth Drivers, Global, 2022–2027
- Vaccines: Growth Restraints, Global, 2022–2027
- Vaccines: Vaccine Coverage Rate by Type and Region, Global, 2021
- COVID-19 Vaccines: Vaccines in Development by Technology Type, Global, 2022
- Vaccines: Number of Vaccines in Clinical Study by Stage of Development, Global, 2021
- Vaccines: Percent and Number of Pipeline Studies by Funding Authority, Global, 2021
- Vaccines: Supply Chain Key Stakeholders, Global, 2021
- Vaccines: Doses of Key Vaccines Procured by UNICEF, Global, 2021
- Vaccines: Tiered Pricing of Key Pediatric Vaccines, Global, 2021
- Vaccines: Applications for Key Stakeholders, Global, 2022–2027
- Vaccines: Key Partnerships and Collaborations, by Company, Global, 2020–2022
- Vaccines: Key Manufacturing Partnerships with Bio-CDMOs, The US, 2021
- Vaccines: Key Manufacturing Partnerships with Bio-CDMOs, Europe, 2021
- Traditional Vaccines: Key Growth Metrics, Global, 2021
- Traditional Vaccines: Revenue Forecast, Global, 2021–2027
- Traditional Vaccines: Revenue Forecast by Technology Type, Global, 2021–2027
- Traditional Vaccines: Percent Revenue Forecast by Technology Type, Global, 2021 and 2027
- Traditional Vaccines: Revenue and Percent Share by Production System, Global, 2021
- Traditional Vaccines: Percent of Revenue by Region, Global, 2021
- Traditional Vaccines: Competitive Environment, Global, 2021
- Traditional Vaccines: Revenue Share of Top Participants, Global, 2021
- Covid-19 Vaccines: Key Growth Metrics, Global, 2021
- COVID-19 Vaccines: Revenue and Percent of Revenue by Technology Type, Global, 2021
- COVID-19 Vaccines: Revenue and Percent of Revenue by Production System, Global, 2021
- COVID-19 Vaccines: Percent of Revenue by Region, Global, 2021
- COVID-19 Vaccines: Competitive Environment, Global, 2021
- COVID-19 Vaccines: Revenue Share of Top Participants, Global, 2021
- Vaccines: Promising Key mRNA Vaccines in the Pipeline, by Disease Area, Global, 2021
- Vaccines: Promising Key DNA Vaccines in the Pipeline, by Disease Area, Global, 2021
- Vaccines: Proportion of mRNA-based vaccines Clinical Trials, by Therapy Area, Global, 2021
- Vaccines: Key Companies with RSV Vaccines in the Pipeline by Clinical Study Phases, Global, 2022
Speak directly with our analytics experts for tailored recommendations.
Recent related Healthcare research
15 Sep 2026 | Global | Market Research
Vendor Profiles: Advanced Wound Care Management Market, Global, 2025
The wound care market is being transformed by advanced technologies and evolving care models that focus on improving patient outcomes and reducing healthcare costs. Innovations such as smart sensor-embedded dressings, artificial intelligence (AI)-based wound imaging systems, enhanced negative pressu...
11 Sep 2026 | Global | Frost Radar
Frost Radar™: Pharmaceutical Commercialization Solutions and Services, 2026
Pharmaceutical commercialization is a multidimensional concept in the successful launch and distribution of a drug. The process includes the development of a pricing strategy that reflects the drug’s value, negotiation with payers to ensure drug cost coverage, regulatory compliance, and the generati...
07 Sep 2026 | Global | Technology Research
Synthetic Antibodies and AI-Optimized Immunotherapies
Artificial intelligence is becoming increasingly relevant to antibody discovery and immunotherapy development, supporting target identification, de novo antibody design, antibody engineering, clinical intelligence, and bioprocessing. Advances in generative AI, protein language models, diffusion mode...
28 Aug 2026 | Global | Technology Research
Innovations and Growth Opportunities in Advanced Medical Devices, Artificial Intelligence Solutions, Digital Solutions, and Medical Imaging Solutions
The latest issue of Advanced MedTech Technology Opportunity Engine (TOE) spotlights a diverse slate of innovations across advanced medical devices, artificial intelligence solutions, digital solutions, and medical imaging solutions.The issue features advanced medical devices such as active bioelectr...
27 Aug 2026 | Global | Frost Radar
Frost Radar: AI-Powered Molecular Diagnostics, 2026
AI-powered molecular diagnostics is an emerging and moderately fragmented industry that includes molecular diagnostics companies, precision medicine platforms, sequencing specialists, AI-driven analytics providers, and disease-focused biotechnology companies. No single company has dominated, present...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
Research Highlights
- Traditional and COVID-19 vaccine market size, including key segments from 2022 to 2027
- Dynamics around COVID-19 vaccination and the path to endemicity
- Role of advancements, such as decentralization, technologies, and new modalities, in driving the vaccine value-chain transformation
- The current and future R&D and investment outlook, and its evolution
- Strategic time-defined growth opportunities for ecosystem participants to focus on in the near future
| Deliverable Type | Market Research |
|---|---|
| Author | Mrinal Kerhalkar |
| Industries | Healthcare |
| No Index | No |
| Is Prebook | No |
| List of Charts and Figures | Vaccines: Growth Opportunity Matrix, Global, 2022–2027~ Vaccines: Growth Drivers, Global, 2022–2027~ Vaccines: Growth Restraints, Global, 2022–2027~ Vaccines: Vaccine Coverage Rate by Type and Region, Global, 2021~ COVID-19 Vaccines: Vaccines in Development by Technology Type, Global, 2022~ Vaccines: Number of Vaccines in Clinical Study by Stage of Development, Global, 2021~ Vaccines: Percent and Number of Pipeline Studies by Funding Authority, Global, 2021~ Vaccines: Supply Chain Key Stakeholders, Global, 2021~ Vaccines: Doses of Key Vaccines Procured by UNICEF, Global, 2021~ Vaccines: Tiered Pricing of Key Pediatric Vaccines, Global, 2021~ Vaccines: Applications for Key Stakeholders, Global, 2022–2027~ Vaccines: Key Partnerships and Collaborations, by Company, Global, 2020–2022~ Vaccines: Key Manufacturing Partnerships with Bio-CDMOs, The US, 2021~ Vaccines: Key Manufacturing Partnerships with Bio-CDMOs, Europe, 2021~ Traditional Vaccines: Key Growth Metrics, Global, 2021~ Traditional Vaccines: Revenue Forecast, Global, 2021–2027~ Traditional Vaccines: Revenue Forecast by Technology Type, Global, 2021–2027~ Traditional Vaccines: Percent Revenue Forecast by Technology Type, Global, 2021 and 2027~ Traditional Vaccines: Revenue and Percent Share by Production System, Global, 2021~ Traditional Vaccines: Percent of Revenue by Region, Global, 2021~ Traditional Vaccines: Competitive Environment, Global, 2021~ Traditional Vaccines: Revenue Share of Top Participants, Global, 2021~ Covid-19 Vaccines: Key Growth Metrics, Global, 2021~ COVID-19 Vaccines: Revenue and Percent of Revenue by Technology Type, Global, 2021~ COVID-19 Vaccines: Revenue and Percent of Revenue by Production System, Global, 2021~ COVID-19 Vaccines: Percent of Revenue by Region, Global, 2021~ COVID-19 Vaccines: Competitive Environment, Global, 2021~ COVID-19 Vaccines: Revenue Share of Top Participants, Global, 2021~ Vaccines: Promising Key mRNA Vaccines in the Pipeline, by Disease Area, Global, 2021~ Vaccines: Promising Key DNA Vaccines in the Pipeline, by Disease Area, Global, 2021~ Vaccines: Proportion of mRNA-based vaccines Clinical Trials, by Therapy Area, Global, 2021~ Vaccines: Key Companies with RSV Vaccines in the Pipeline by Clinical Study Phases, Global, 2022~ |
| Podcast | No |
| WIP Number | PCCF-01-00-00-00 |
Global Vaccine Growth Opportunities
$4,950.00
Special Price $3,712.50 save 25 %